Drugs / CC-90011
CC-90011
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04748848 | Oct 2021 → Mar 2022 | myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04628988 | Jul 2021 → May 2023 | prostate neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03850067 | Mar 2019 → Jul 2024 | small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02875223 | Aug 2016 → Mar 2024 | non-Hodgkin lymphoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04350463 | Jul 2020 → Dec 2023 | neoplasm | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03850067 ↗ |
| Known as | Pulrodemstat benzenesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651180 ↗ |
| Known as | PULRODEMSTAT BESILATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651180 ↗ |
| Action | Inhibit | “CC-90011 is an oral, potent, selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1)” PMID 35737639 ↗ Jun 2022 |
| Modality | Small molecule | — CHEMBL4651180 ↗ |
| Route | Oral | “explore escalating oral doses of CC-90011” NCT02875223 ↗ |